NCT07153757View on ClinicalTrials.gov

De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

2,934

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2033

Study Completion Date

September 1, 2033

Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
DRUG

Endocrine Therapy of Physician's Choice

This study employs a 2-3 year de-escalated endocrine therapy regimen in the experimental group, which distinguishes it from other escalation therapy studies.

Trial Locations (1)

200032

270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER